N4 Pharma PLC - N4 101 In Vitro Results
RNS
Latest announcements
Announcement summary
N4 Pharma PLC - N4 101 In Vitro Results
In Layman's terms:
N4 Pharma’s in vitro (lab-based) experiments show their oral IBD treatment is working as intended. Imagine Nuvec® as a delivery truck: it carries two packages (siRNA and mRNA) to specific locations (macrophages, which are immune cells involved in inflammation). The results show these trucks not only deliver the packages efficiently but can handle two at once—one to turn off inflammatory signals (TNFalpha) and another to boost anti-inflammatory ones (IL-10). This demonstrates the potential of Nuvec® for creating a more precise and effective treatment for IBD. Next up: testing this approach in live models!
Ask a question
Your question will be visible to everyone.
Investor Q&As
Start the conversation
Ask Thalia Therapeutics a question about this announcement.